Disc Medicine publishes corporate presentation on hematology pipeline targeting heme, iron pathways

The pipeline update also included iron-regulation antibodies DISC-0974 and DISC-3405 targeting hepcidin pathways for anemia and iron-restriction indications; both remain investigational.

Disc Medicine highlighted late-stage development of bitopertin, an oral GlyT1 inhibitor aimed at reducing disease-causing PPIX in erythropoietic protoporphyria.

• Phase 3 APOLLO trial enrollment completed in March 2026; topline data expected in Q4 2026; 183 patients ages 12+ randomized 1:1.
• APOLLO co-primary endpoints: pain-free sunlight exposure time in the final month of treatment; % change in whole-blood metal-free PPIX at 6 months.
• Phase 2 AURORA data cited: 40% reduction in PPIX vs. baseline; 75% lower phototoxic reaction rate vs. placebo; 86% reported EPP “much better.”